![]() ![]() ![]() In WHO grade III glioma the outcome in terms of progression free survival (PFS) and overall survival (OS) is better compared to GB patients but the incidence of local recurrence is still considerable, above all in the case of astrocytic tumors subtypes. However, survival remains poor with a median survival time and 3-year survival rate of 10–12 months and 6–8 % respectively. Surgery, followed by concomitant and adjuvant chemo-radiotherapy with temozolomide (TMZ), represents the standard of care for newly diagnosed glioblastoma (GB). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |